Gout Management

Epidemiology and Pathophysiology

• Approximately 8 million people in the United States have gout, a common inflammatory arthritis characterized by acute intermittent episodes of synovitis causing joint swelling and pain, resulting from the crystallization of excess urate in the body as monosodium urate crystals in joint fluid, cartilage, bones, tendons, and other tissues 1
• Gout is associated with common comorbidities, including chronic kidney disease (CKD), hypertension, heart failure, and obesity, particularly in elderly patients 2, 3

Diagnosis

• The gold standard diagnosis for gout is synovial fluid analysis for monosodium urate (MSU) crystal identification, with 100% specificity when properly performed, as recommended by the American College of Rheumatology 2, 4
• Clinical diagnosis based on suggestive features and hyperuricemia can be used when synovial fluid analysis is not feasible, with consideration of imaging (particularly ultrasound) to search for MSU crystal deposition, as suggested by the European League Against Rheumatism 2

Treatment

• The American College of Physicians recommends first-line treatments, including NSAIDs, colchicine (low-dose is as effective as high-dose with fewer gastrointestinal adverse events), and corticosteroids (oral, intravenous, or intra-articular), which have high-strength evidence showing they reduce pain in acute gout 1
• High-strength evidence shows that prophylaxis with daily colchicine or NSAIDs reduces the risk for acute gout attacks by at least half in patients starting urate-lowering therapy 1
• Moderate-strength evidence indicates that prophylaxis duration should be longer than 8 weeks 1
• For acute management of gout flares in elderly patients, corticosteroids, NSAIDs, or colchicine can be used, with caution advised when using NSAIDs due to renal, cardiovascular, and GI risks, as recommended by the American College of Physicians 5

Urate-Lowering Therapy (ULT)

• Urate-lowering therapy (ULT) is generally not recommended for first flare unless specific risk factors exist, such as CKD stage >3, serum urate >9 mg/dL, or urolithiasis, according to the American College of Rheumatology 3
• Allopurinol is the preferred first-line agent for ULT, even in those with moderate-to-severe CKD, as recommended by the European League Against Rheumatism 3
• Prophylactic urate-lowering therapy should be considered in high-risk patients, as recommended by the American Heart Association, EULAR, and the Annals of the Rheumatic Diseases 6, 7, 8

Lifestyle Modifications and Comorbidities

• Limiting alcohol consumption, particularly beer and spirits, is recommended for elderly patients with gout, as suggested by the American College of Rheumatology 2
• Asymptomatic hyperuricemia alone is not an indication for ULT, according to the American College of Rheumatology 3
• Thiazide diuretics are not recommended for patients with severe renal impairment (eGFR <30 mL/min/1.73m²), a history of gout, or those with multiple metabolic risk factors increasing the risk of new-onset diabetes, as per the European Society of Cardiology and the American Heart Association 9, 10, 11
• The following table shows the odds ratio for thiazide diuretics and gout development:

• Patients on thiazide diuretics should be regularly monitored for elevated serum urate levels, signs of gout, and hyperuricemia without symptoms, with first-line options for acute flares including colchicine, NSAIDs, oral corticosteroids, and intra-articular corticosteroid injection, as recommended by the American College of Rheumatology, the Annals of the Rheumatic Diseases, and EULAR 12, 13, 7, 14, 5, 6
• Alternative first-line agents such as ACE inhibitors, ARBs, or calcium channel blockers should be considered for patients at risk of gout, as suggested by the American College of Cardiology and the Annals of the Rheumatic Diseases 15, 6
• Loop diuretics are preferred over thiazides in patients with an eGFR <30 mL/min/m², as they maintain efficacy in advanced kidney disease, as suggested by the American Journal of Kidney Diseases and the American Heart Association 16, 15
• In heart failure patients, loop diuretics are generally preferred for significant fluid retention, while thiazides may be considered in hypertensive heart failure patients with only mild fluid retention, as recommended by the American College of Cardiology and the American Heart Association 15, 17, 18